Company Performance Metrics
- Mark Erlander: Chief Scientific OfficerPast Role: Hologic, Chief Scientific Officer
- Stephen Zaniboni: Chief Financial OfficerPast Role: Awarepoint, CFO
AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient’s tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific
prognosis or individual risk assessment, and will eventually provide information critical to predict treatment response to a given therapeutic regimen.
AviaraDx offers diagnostic tests to qualified physicians or laboratories through its certified CLIA and CAP laboratory service operations. The company's first two diagnostic test offerings are based on its proprietary technologies used in molecular classification of metastatic cancer (CancerTYPE ID™) and its test to assess risk of recurrence in certain breast cancer patients, (H/I™ (HOXB13/IL17BR).
